title: Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence.
abstract: BACKGROUND
  Statins are currently the preferred pharmacological therapy in individuals with familial hypercholesterolemia (FH) with the aim to prevent premature atherosclerosis. In adults, these agents have been proven to be safe and well tolerated; however, non-adherence is a significant clinical issue.
  
  
  OBJECTIVE
  In this study, we evaluated tolerability and adherence to statin therapy in young adult FH patients 10 years after this was initiated in their childhood.
  
  
  METHODS
  A questionnaire including items on medical history, adherence and reasons for discontinuation was sent to 214 young adult FH patients that initiated statin therapy at least 10 years ago. Tolerability was defined as 100% minus the percentage of patients that discontinued statin therapy due to side effects. Adherence was defined as the extent to which patients took their medication as prescribed by their physician. We labelled patients adherent if they took 80% or more of their pills in the month preceding our assessment.
  
  
  RESULTS
  Follow-up was successful in 205 (95.8%) subjects (age 18-30 years). A history of side effects was reported by 40 (19.5%) of the patients, and mainly consisted of muscle complaints and gastrointestinal symptoms. Three patients (1.5%) discontinued statin therapy because of side effects. Rhadbomyolysis or other serious adverse events were not reported. In fact, 169 (82.4%) of 205 patients remained on statin treatment and 78.7% (148 out of 188) were adherent. None of the patient characteristics were significantly associated with adherence.
  
  
  CONCLUSIONS
  Individuals with FH who started statin therapy in childhood demonstrated good adherence during ten years of treatment. Furthermore, statin therapy was well tolerated; only a small minority discontinued therapy because of side effects and the side effects that were reported were mild in nature.
authors: Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands, j.a.braamskamp@amc.uva.nl.
authors: Marjet J A M
authors: MJ
authors: Braamskamp
authors: D Meeike
authors: DM
authors: Kusters
authors: Hans J
authors: HJ
authors: Avis
authors: Ellen M A
authors: EM
authors: Smets
authors: Frits A
authors: FA
authors: Wijburg
authors: John J P
authors: JJ
authors: Kastelein
authors: Albert
authors: A
authors: Wiegman
authors: Barbara A
authors: BA
authors: Hutten
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D008297:Male; D055118:Medication Adherence; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references: JAMA. 2002 Jul 24-31;288(4):455-61
references: 12132975
references: JAMA. 2002 Jul 24-31;288(4):462-7
references: 12132976
references: JAMA. 2003 Apr 2;289(13):1681-90
references: 12672737
references: Atherosclerosis. 2003 May;168(1):1-14
references: 12732381
references: JAMA. 2004 Jul 21;292(3):331-7
references: 15265847
references: Clin Chem. 1972 Jun;18(6):499-502
references: 4337382
references: Diabetes Care. 1997 Jan;20(1):36-44
references: 9028691
references: Cardiovasc Drugs Ther. 2004 Nov;18(6):475-81
references: 15770435
references: N Engl J Med. 2005 Aug 4;353(5):487-97
references: 16079372
references: Lancet. 2005 Oct 8;366(9493):1267-78
references: 16214597
references: Eur J Clin Pharmacol. 2005 Oct;61(9):667-74
references: 16151763
references: J Adolesc Health. 2006 Jan;38(1):13-7
references: 16387243
references: Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14
references: 16453090
references: Circulation. 2006 Dec 19;114(25):2788-97
references: 17159064
references: Circulation. 2007 Apr 10;115(14):1948-67
references: 17377073
references: Br J Clin Pharmacol. 2007 Jun;63(6):698-708
references: 17214831
references: J Acquir Immune Defic Syndr. 2009 May 1;51(1):65-71
references: 19282780
references: Inflamm Bowel Dis. 2009 Jun;15(6):837-44
references: 19107771
references: Circulation. 2009 Jun 16;119(23):3028-35
references: 19528344
references: Am J Med. 2009 Jul;122(7):647-55
references: 19559167
references: Eur J Clin Pharmacol. 2009 Oct;65(10):1013-24
references: 19529927
references: Ann Allergy Asthma Immunol. 2009 Oct;103(4):325-31
references: 19852197
references: PLoS One. 2010;5(2):e9220
references: 20169164
references: Atherosclerosis. 2010 Mar;209(1):189-94
references: 19818960
references: Ann Pharmacother. 2010 Sep;44(9):1410-21
references: 20702755
references: J Clin Lipidol. 2010 Nov-Dec;4(6):462-71
references: 21122692
references: BMJ. 2011;342:d12
references: 21257657
references: J Clin Lipidol. 2011 May-Jun;5(3):133-40
references: 21600517
references: Horm Res Paediatr. 2011;76 Suppl 1:47-51
references: 21778749
references: JAMA. 2014 Sep 10;312(10):1055-7
references: 25203086